Literature DB >> 29272894

The Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts.

Johannes R Hov1,2,3, Tom H Karlsen1,2,3.   

Abstract

The close relationship between primary sclerosing cholangitis (PSC) and inflammatory bowel disease has inspired hypothetical models in which gut bacteria or bacterial products are key players in PSC pathogenesis. Several studies using high-throughput sequencing technology to characterize the gut microbiota in PSC have been published over the past years. They all report reduced diversity and significant shifts in the overall composition of the gut microbiota. However, it remains unclear as to whether the observed changes are primary or secondary to PSC development and further studies are needed to assess the biological implications of the findings. In the present article, we review the published data in perspective of similar studies in other diseases. We discuss aspects of methodology and study design that are relevant to interpretation of the data. Furthermore, we propose that interpretation and further assessments of findings are structured into conceptual compartments, and elaborate three such possible concepts relating to immune function (the "immunobiome"), host metabolism (the "endobiome"), and dietary and xenobiotic factors (the "xenobiome") in PSC. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2017        PMID: 29272894     DOI: 10.1055/s-0037-1608801

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  17 in total

Review 1.  Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.

Authors:  Mai Sedki; Cynthia Levy
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

Review 2.  Studying the Exposome to Understand the Environmental Determinants of Complex Liver Diseases.

Authors:  Angela C Cheung; Douglas I Walker; Brian D Juran; Gary W Miller; Konstantinos N Lazaridis
Journal:  Hepatology       Date:  2019-12-24       Impact factor: 17.425

Review 3.  Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?

Authors:  Lu Jiang; Bernd Schnabl
Journal:  Physiology (Bethesda)       Date:  2020-07-01

Review 4.  [Primary sclerosing cholangitis : Current diagnostics and treatment].

Authors:  T Liwinski; C Schramm
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

Review 5.  Novel approaches to liver disease diagnosis and modeling.

Authors:  André G Oliveira; Romina Fiorotto
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

6.  Alterations in Skin Microbiomes of Patients With Cirrhosis.

Authors:  Jasmohan S Bajaj; Andrew Fagan; Masoumeh Sikaroodi; Genta Kakiyama; Hajme Takei; Yordanos Degefu; William M Pandak; Phillip B Hylemon; Michael Fuchs; Binu John; Douglas M Heuman; Edith Gavis; Hiroshi Nittono; Rohan Patil; Patrick M Gillevet
Journal:  Clin Gastroenterol Hepatol       Date:  2019-03-21       Impact factor: 11.382

7.  Personalized inherent randomness of the immune system is manifested by an individualized response to immune triggers and immunomodulatory therapies: a novel platform for designing personalized immunotherapies.

Authors:  Madi El-Haj; Dimitri Kanovitch; Yaron Ilan
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

Review 8.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

Review 9.  New Therapeutic Targets in Autoimmune Cholangiopathies.

Authors:  Alessio Gerussi; Martina Lucà; Laura Cristoferi; Vincenzo Ronca; Clara Mancuso; Chiara Milani; Daphne D'Amato; Sarah Elizabeth O'Donnell; Marco Carbone; Pietro Invernizzi
Journal:  Front Med (Lausanne)       Date:  2020-04-07

Review 10.  Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities.

Authors:  Mette Vesterhus; Tom Hemming Karlsen
Journal:  J Gastroenterol       Date:  2020-03-28       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.